Overbrook Management Corp Has $3.02 Million Position in Royalty Pharma plc (NASDAQ:RPRX)

Overbrook Management Corp reduced its position in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 16.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 118,408 shares of the biopharmaceutical company's stock after selling 22,500 shares during the period. Overbrook Management Corp's holdings in Royalty Pharma were worth $3,021,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of RPRX. Aurora Investment Counsel grew its stake in shares of Royalty Pharma by 1.0% in the 3rd quarter. Aurora Investment Counsel now owns 50,441 shares of the biopharmaceutical company's stock valued at $1,427,000 after purchasing an additional 512 shares during the period. GAMMA Investing LLC raised its stake in Royalty Pharma by 31.4% during the fourth quarter. GAMMA Investing LLC now owns 2,471 shares of the biopharmaceutical company's stock worth $63,000 after acquiring an additional 590 shares in the last quarter. Xponance Inc. lifted its holdings in shares of Royalty Pharma by 1.9% during the second quarter. Xponance Inc. now owns 31,704 shares of the biopharmaceutical company's stock valued at $836,000 after acquiring an additional 606 shares during the period. EverSource Wealth Advisors LLC boosted its stake in shares of Royalty Pharma by 32.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,698 shares of the biopharmaceutical company's stock valued at $76,000 after purchasing an additional 655 shares in the last quarter. Finally, Values First Advisors Inc. grew its holdings in shares of Royalty Pharma by 7.6% in the 3rd quarter. Values First Advisors Inc. now owns 10,412 shares of the biopharmaceutical company's stock worth $295,000 after purchasing an additional 738 shares during the last quarter. 54.35% of the stock is currently owned by institutional investors.

Royalty Pharma Trading Down 0.6 %

Shares of Royalty Pharma stock traded down $0.20 during trading on Monday, reaching $30.75. 2,886,986 shares of the company were exchanged, compared to its average volume of 2,554,709. Royalty Pharma plc has a twelve month low of $24.05 and a twelve month high of $31.66. The business has a 50-day moving average price of $26.31 and a 200-day moving average price of $27.20. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $18.12 billion, a price-to-earnings ratio of 15.93 and a beta of 0.47.

Royalty Pharma Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 21st will be issued a $0.22 dividend. The ex-dividend date is Friday, February 21st. This is a positive change from Royalty Pharma's previous quarterly dividend of $0.21. This represents a $0.88 annualized dividend and a yield of 2.86%. Royalty Pharma's dividend payout ratio (DPR) is 43.52%.

Analyst Upgrades and Downgrades

RPRX has been the topic of several research analyst reports. TD Cowen raised shares of Royalty Pharma to a "strong-buy" rating in a research note on Tuesday, December 24th. Citigroup dropped their price target on Royalty Pharma from $60.00 to $40.00 and set a "buy" rating for the company in a report on Friday, October 25th. Finally, StockNews.com upgraded Royalty Pharma from a "hold" rating to a "buy" rating in a report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $41.67.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.